JP2008514703A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008514703A5 JP2008514703A5 JP2007534673A JP2007534673A JP2008514703A5 JP 2008514703 A5 JP2008514703 A5 JP 2008514703A5 JP 2007534673 A JP2007534673 A JP 2007534673A JP 2007534673 A JP2007534673 A JP 2007534673A JP 2008514703 A5 JP2008514703 A5 JP 2008514703A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- cycloalkyl
- alkoxy
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000000217 alkyl group Chemical group 0.000 claims 67
- 150000001875 compounds Chemical class 0.000 claims 25
- 239000000203 mixture Substances 0.000 claims 25
- 229910052736 halogen Inorganic materials 0.000 claims 24
- 150000002367 halogens Chemical class 0.000 claims 24
- 125000003545 alkoxy group Chemical group 0.000 claims 18
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 14
- 125000003282 alkyl amino group Chemical group 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 10
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 10
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- -1 cyano, hydroxy Chemical group 0.000 claims 6
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 125000002393 azetidinyl group Chemical group 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 5
- 125000003386 piperidinyl group Chemical group 0.000 claims 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 4
- 239000003146 anticoagulant agent Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 125000005647 linker group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 230000000702 anti-platelet effect Effects 0.000 claims 2
- 229940127219 anticoagulant drug Drugs 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 206010002388 Angina unstable Diseases 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 208000033463 Ischaemic neuropathy Diseases 0.000 claims 1
- 206010038563 Reocclusion Diseases 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010043647 Thrombotic Stroke Diseases 0.000 claims 1
- 229940123987 Thromboxane A2 receptor antagonist Drugs 0.000 claims 1
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003529 anticholesteremic agent Substances 0.000 claims 1
- 229940127226 anticholesterol agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000003420 antiserotonin agent Substances 0.000 claims 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 229940072645 coumadin Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003480 fibrinolytic effect Effects 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 229940118179 lovenox Drugs 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000003868 thrombin inhibitor Substances 0.000 claims 1
- 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 claims 1
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 1
- 0 CC=*(c1ccc(OC)[s]1)NC(Nc(cc1)ccc1N(COc(c1c2)cc(NC)c2F)C1=O)=O Chemical compound CC=*(c1ccc(OC)[s]1)NC(Nc(cc1)ccc1N(COc(c1c2)cc(NC)c2F)C1=O)=O 0.000 description 4
- BVLVBLYZSSBNKL-UHFFFAOYSA-N C/C=S(/c([s]1)ccc1Cl)\NC(Nc(c(F)cc(N(COc(c1c2)cc(NC)c2F)C1=O)c1)c1F)=O Chemical compound C/C=S(/c([s]1)ccc1Cl)\NC(Nc(c(F)cc(N(COc(c1c2)cc(NC)c2F)C1=O)c1)c1F)=O BVLVBLYZSSBNKL-UHFFFAOYSA-N 0.000 description 1
- GTJUJMDVJWGZSV-UHFFFAOYSA-N C/C=S(/c1ccc(C)[s]1)\NC(Nc(cc1)ncc1N(COc(c1c2)cc(NC)c2F)C1=O)=O Chemical compound C/C=S(/c1ccc(C)[s]1)\NC(Nc(cc1)ncc1N(COc(c1c2)cc(NC)c2F)C1=O)=O GTJUJMDVJWGZSV-UHFFFAOYSA-N 0.000 description 1
- OCNDYBAHYJKQCK-UHFFFAOYSA-N CNc(cc(c1c2)OCN(c(cc3)ccc3C(NS(C)(c([s]3)ccc3Cl)=O)=O)C1=O)c2F Chemical compound CNc(cc(c1c2)OCN(c(cc3)ccc3C(NS(C)(c([s]3)ccc3Cl)=O)=O)C1=O)c2F OCNDYBAHYJKQCK-UHFFFAOYSA-N 0.000 description 1
- KGWVNJJUMGZQND-UHFFFAOYSA-N CNc(cc(c1c2)OCN(c(ccc(NC(NS(c([s]3)ccc3Cl)OC)=O)c3)c3OC)C1=O)c2F Chemical compound CNc(cc(c1c2)OCN(c(ccc(NC(NS(c([s]3)ccc3Cl)OC)=O)c3)c3OC)C1=O)c2F KGWVNJJUMGZQND-UHFFFAOYSA-N 0.000 description 1
- LWRDKCOFIXEBNQ-UHFFFAOYSA-N CNc(cc(c1c2)OCN(c3cccc(CNC(NS(c([s]4)ccc4Cl)(=O)=O)=O)c3)C1=O)c2F Chemical compound CNc(cc(c1c2)OCN(c3cccc(CNC(NS(c([s]4)ccc4Cl)(=O)=O)=O)c3)C1=O)c2F LWRDKCOFIXEBNQ-UHFFFAOYSA-N 0.000 description 1
- OVBNRMWLXYEIQR-UHFFFAOYSA-N Cc([s]1)ccc1/S(/NC(Nc(c(C)cc(N(COc(c1c2)cc(NC)c2F)C1=O)c1)c1OC)=O)=[O]/C Chemical compound Cc([s]1)ccc1/S(/NC(Nc(c(C)cc(N(COc(c1c2)cc(NC)c2F)C1=O)c1)c1OC)=O)=[O]/C OVBNRMWLXYEIQR-UHFFFAOYSA-N 0.000 description 1
- ASCRMSOACALAGG-UHFFFAOYSA-N Cc(cc(c(OCN1c2ccc(C(NS(c([s]3)ccc3Cl)(=O)=O)=O)c(F)c2)c2)C1=O)c2NC Chemical compound Cc(cc(c(OCN1c2ccc(C(NS(c([s]3)ccc3Cl)(=O)=O)=O)c(F)c2)c2)C1=O)c2NC ASCRMSOACALAGG-UHFFFAOYSA-N 0.000 description 1
- BRQCPFPVSBLYJG-UHFFFAOYSA-N Cc1cc(N(COc(c2c3)cc(NC)c3F)C2=O)cc(Cl)c1NC(NSc([s]1)ccc1Cl)=O Chemical compound Cc1cc(N(COc(c2c3)cc(NC)c3F)C2=O)cc(Cl)c1NC(NSc([s]1)ccc1Cl)=O BRQCPFPVSBLYJG-UHFFFAOYSA-N 0.000 description 1
- VDUPLNMVHVDKNL-UHFFFAOYSA-N Cc1ccc(SNC(Nc(cc2)ccc2N(COc(c2c3)cc(NC)c3F)C2=O)=O)[s]1 Chemical compound Cc1ccc(SNC(Nc(cc2)ccc2N(COc(c2c3)cc(NC)c3F)C2=O)=O)[s]1 VDUPLNMVHVDKNL-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61456404P | 2004-09-29 | 2004-09-29 | |
| PCT/US2005/034246 WO2006039212A2 (en) | 2004-09-29 | 2005-09-26 | Substituted 2h-1,3-benzoxazin-4(3h)-ones |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008514703A JP2008514703A (ja) | 2008-05-08 |
| JP2008514703A5 true JP2008514703A5 (https=) | 2008-09-18 |
Family
ID=36142983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007534673A Ceased JP2008514703A (ja) | 2004-09-29 | 2005-09-26 | 置換２ｈ−１，３−ベンゾオキサジン−４（３ｈ）−オン |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7205296B2 (https=) |
| EP (1) | EP1812429A4 (https=) |
| JP (1) | JP2008514703A (https=) |
| KR (1) | KR20070064356A (https=) |
| CN (1) | CN101031565B (https=) |
| AU (1) | AU2005292314B2 (https=) |
| BR (1) | BRPI0516181A (https=) |
| CA (1) | CA2581638A1 (https=) |
| IL (1) | IL182180A0 (https=) |
| MX (1) | MX2007003836A (https=) |
| NZ (1) | NZ554211A (https=) |
| WO (1) | WO2006039212A2 (https=) |
| ZA (1) | ZA200702688B (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7834023B2 (en) * | 2006-09-20 | 2010-11-16 | Portola Pharmaceuticals, Inc. | Substituted dihydroquinazolines as platelet ADP receptor inhibitors |
| US7740693B2 (en) * | 2007-10-01 | 2010-06-22 | Honeywell International Inc. | Organic fluorescent sulfonyl ureido benzoxazinone pigments |
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| RU2014121984A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств |
| CN104718188B (zh) * | 2012-05-22 | 2018-08-21 | 基因泰克公司 | N-取代的苯甲酰胺类及其在治疗疼痛中的用途 |
| KR101663436B1 (ko) | 2012-07-06 | 2016-10-06 | 제넨테크, 인크. | N-치환된 벤즈아미드 및 이의 사용 방법 |
| HK1213181A1 (zh) | 2012-09-27 | 2016-06-30 | Portola Pharmaceuticals, Inc. | 雙環氧雜內酰胺激酶抑制劑 |
| RU2015143906A (ru) | 2013-03-14 | 2017-04-18 | Дженентек, Инк. | Замещенные триазолопиридины и способы их применения |
| BR112015023397A2 (pt) | 2013-03-15 | 2017-07-18 | Genentech Inc | benzoxazois substituídos e métodos de uso dos mesmos |
| WO2015078374A1 (en) | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| JP2017525677A (ja) | 2014-07-07 | 2017-09-07 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| HRP20220522T1 (hr) | 2014-08-04 | 2022-06-10 | Nuevolution A/S | Proizvoljno kondenzirani heterociklil-supstituirani derivati pirimidina koji su korisni za liječenje upalnih, metaboličkih, onkoloških i autoimunih bolesti |
| MA41051B1 (fr) | 2014-10-06 | 2020-11-30 | Vertex Pharma | Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose |
| SI3259253T1 (sl) | 2015-02-16 | 2020-07-31 | The University Of Queensland | Sulfonilsečnine in sorodne spojine ter njihova uporaba |
| HK1252567A1 (zh) | 2015-05-22 | 2019-05-31 | 基因泰克公司 | 被取代的苯甲酰胺和其使用方法 |
| JP2018526371A (ja) | 2015-08-27 | 2018-09-13 | ジェネンテック， インコーポレイテッド | 治療化合物及びその使用方法 |
| CA2999769A1 (en) | 2015-09-28 | 2017-04-06 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| EP3380466A1 (en) | 2015-11-25 | 2018-10-03 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
| EP3436432B1 (en) | 2016-03-30 | 2021-01-27 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| CA3019380A1 (en) | 2016-03-31 | 2017-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CN109803962B (zh) | 2016-09-30 | 2022-04-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物 |
| PE20190980A1 (es) | 2016-10-17 | 2019-07-09 | Genentech Inc | Compuestos terapeuticos y metodos para utilizarlos |
| MD3551622T2 (ro) | 2016-12-09 | 2021-03-31 | Vertex Pharma | Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului |
| JP2020511511A (ja) | 2017-03-24 | 2020-04-16 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体 |
| US11253509B2 (en) | 2017-06-08 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| NZ760129A (en) | 2017-07-07 | 2025-12-19 | Inflazome Ltd | Novel sulfonamide carboxamide compounds |
| MA49631A (fr) | 2017-07-17 | 2020-05-27 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| JP7121794B2 (ja) | 2017-08-02 | 2022-08-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピロリジン化合物を調製するためのプロセス |
| MA49903A (fr) | 2017-08-15 | 2020-06-24 | Inflazome Ltd | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 |
| UY37848A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
| EP3668843A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| US10807994B2 (en) | 2017-10-09 | 2020-10-20 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| WO2019074979A1 (en) | 2017-10-09 | 2019-04-18 | Girafpharma, Llc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| WO2019079760A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| EP3720849A2 (en) | 2017-12-08 | 2020-10-14 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| AR114263A1 (es) | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| US11905252B2 (en) | 2018-03-02 | 2024-02-20 | Inflazome Limited | Compounds |
| US10947251B2 (en) | 2018-03-30 | 2021-03-16 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| US20220162229A1 (en) * | 2019-04-09 | 2022-05-26 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| US20220168313A1 (en) * | 2019-04-09 | 2022-06-02 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| CN113939296A (zh) | 2019-04-09 | 2022-01-14 | 诺维逊生物股份有限公司 | 杂环化合物及其用途 |
| EP4074707A4 (en) * | 2019-12-10 | 2024-01-03 | Shanghai Zhimeng Biopharma, Inc. | COMPOUND WITH NEUROPROTECTIVE EFFECT, PREPARATION METHOD AND USE THEREOF |
| MX2022007265A (es) | 2019-12-20 | 2022-09-09 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
| US11685727B2 (en) | 2019-12-20 | 2023-06-27 | Nuevolution A/S | Compounds active towards nuclear receptors |
| CA3174176A1 (en) | 2020-03-31 | 2021-10-07 | Sanne Schroder Glad | Compounds active towards nuclear receptors |
| EP4126874A1 (en) | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Compounds active towards nuclear receptors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI101150B (fi) | 1991-09-09 | 1998-04-30 | Sankyo Co | Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi |
| FR2702477B1 (fr) * | 1993-03-08 | 1995-04-28 | Synthelabo | Dérivés de benzoxazine, leur préparation et leur application en thérapeutique. |
| JP3814742B2 (ja) * | 1996-10-18 | 2006-08-30 | イハラケミカル工業株式会社 | ４−フルオロサリチル酸類 |
| SE9702774D0 (sv) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
| JP2002509152A (ja) | 1998-01-15 | 2002-03-26 | シーオーアール セラピューティクス インコーポレイテッド | 血小板ａｄｐ受容体阻害剤 |
| CA2332608C (en) | 1998-06-17 | 2010-03-23 | Bristol-Myers Squibb Company | Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination |
| US6509348B1 (en) | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
| DK1257550T3 (da) | 2000-02-04 | 2006-03-27 | Portola Pharm Inc | Blodplade-ADP-receptor-inhibitor |
| US6906063B2 (en) * | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| ES2282304T3 (es) | 2000-11-01 | 2007-10-16 | Astellas Pharma Inc. | Procedimiento para seleccionar antiplaquetas. |
| US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
| CA2508623A1 (en) * | 2002-12-06 | 2004-06-24 | Toray Industries, Inc. | Benzomorpholine derivatives |
| AU2004278030C1 (en) * | 2003-10-03 | 2010-12-02 | Portola Pharmaceuticals, Inc. | 2,4-Dioxo-3-quinazolinylaryl sulfonylureas |
| JP4879745B2 (ja) * | 2003-10-03 | 2012-02-22 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 置換イソキノリノン |
-
2005
- 2005-09-26 CN CN2005800328848A patent/CN101031565B/zh not_active Expired - Fee Related
- 2005-09-26 KR KR1020077009902A patent/KR20070064356A/ko not_active Ceased
- 2005-09-26 NZ NZ554211A patent/NZ554211A/en not_active IP Right Cessation
- 2005-09-26 WO PCT/US2005/034246 patent/WO2006039212A2/en not_active Ceased
- 2005-09-26 AU AU2005292314A patent/AU2005292314B2/en not_active Ceased
- 2005-09-26 US US11/236,051 patent/US7205296B2/en not_active Expired - Lifetime
- 2005-09-26 EP EP05798632A patent/EP1812429A4/en not_active Withdrawn
- 2005-09-26 MX MX2007003836A patent/MX2007003836A/es active IP Right Grant
- 2005-09-26 CA CA002581638A patent/CA2581638A1/en not_active Abandoned
- 2005-09-26 JP JP2007534673A patent/JP2008514703A/ja not_active Ceased
- 2005-09-26 ZA ZA200702688A patent/ZA200702688B/en unknown
- 2005-09-26 BR BRPI0516181-9A patent/BRPI0516181A/pt not_active IP Right Cessation
-
2007
- 2007-03-26 IL IL182180A patent/IL182180A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008514703A5 (https=) | ||
| JP2007507519A5 (https=) | ||
| JP2007507551A5 (https=) | ||
| JP2008517983A5 (https=) | ||
| CA2540214A1 (en) | 2,4-dioxo-3-quinazolinylaryl sulfonylureas | |
| CA2498051A1 (en) | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | |
| JP2009543867A5 (https=) | ||
| JP2007533741A5 (ja) | Ｂａｃｅ阻害剤として有用なピロリジン誘導体 | |
| MY139335A (en) | Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists | |
| CR9267A (es) | Derivados de quinazolina para el tratamiento de la tuberculosis latente | |
| JP2009533410A5 (https=) | ||
| NO20070368L (no) | Virale polymeraseinhibitorer | |
| NO20082389L (no) | 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler | |
| NO20053892L (no) | Virale polymeraseinhibitorer | |
| EP1396487A1 (en) | Phenylpyridine carbonyl piperazine derivative | |
| CA2593264A1 (en) | Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| JP2010505906A5 (https=) | ||
| NO943146L (no) | Tienopyrimidinderivater, deres fremstilling og anvendelse | |
| RU2009128966A (ru) | Новые производные аминопиримидина в качестве ингибиторов plr1 | |
| ATE455103T1 (de) | Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate | |
| JP2007231005A5 (https=) | ||
| JP2008519087A5 (https=) | ||
| JP2019537602A5 (https=) | ||
| JP2005536519A5 (https=) | ||
| Zhang et al. | Biarylsulfonamide CCR9 inhibitors for inflammatory bowel disease |